Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT9425-23-MRP-IA: FY23 DoD Melanoma Idea Award

Closed Closed September 22, 2023 Opportunity HT9425-23-MRP-IA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2023.

• Total funding$12.0 million
• Expected awards15
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The FY23 MRP Idea Award supports innovative, untested, exploratory, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods that address at least one of the FY23 MRP Focus Areas in Section II.A.1. Key aspects of the Idea Award: The intent of the Idea Award is to generate novel research avenues for investigation; therefore, novelty and innovation should be key aspects of the proposed research. Research supported by the Idea Award must introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. The proposed project can be exploratory, hypothesis-driven, or hypothesis-generating research but must be based on a strong scientific rationale and a well-developed study design and plan of analysis. The Idea Award is not intended to expand or extend previously published findings or continue a line of research already established in the applicant’s laboratory. Incremental advances, the next logical step, or merely switching the object or method of inquiry from one cancer to another cancer is not considered innovative. The expected outcome of research supported by this award is the generation of robust preliminary data to be used as a foundation for future melanoma-focused research projects. Inclusion of preliminary data is discouraged. Principal Investigators (PIs) proposing projects already supported by significant preliminary data should consider applying to other FY23 MRP funding opportunities for which the inclusion of preliminary data is more appropriate or required. Inclusion of preliminary data other than serendipitous findings is not consistent with the exploratory/innovative nature of this award. If preliminary data are included, they should be unanticipated outcomes or results from an unrelated project or study.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.